Survival rates and tolerability of platinum-based chemotherapy regimens for elderly patients with non-small-cell lung cancer (NSCLC)

Lung Cancer

Volumn 53, Issue 2, 2006, Pages 171-176

  Costa, Guilherme Jorge ^a   Fernandes, Ana Luisa Godoy ^a   Pereira, José Rodrigues ^b   Curtis, J Randall ^c   Santoro, Ilka Lopes ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b Instituto do Cancer Dr Arnaldo   (Brazil)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Chemotherapy; Elderly; Non small cell lung cancer; Survival

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; NAVELBINE; PACLITAXEL; PLATINUM DERIVATIVE;

ADVANCED CANCER; AGED; AGING; ANAMNESIS; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DISEASE EXACERBATION; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FATIGUE; FEMALE; GRANULOCYTOPENIA; HUMAN; INFECTION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUROLOGIC DISEASE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; STATISTICAL ANALYSIS; THROMBOCYTOPENIA; UROGENITAL TRACT DISEASE; VOMITING;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PLATINUM COMPOUNDS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINBLASTINE;

EID: 33745626090     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2006.04.006     Document Type: Article

References (22)

1. Bunn P.A., and Lilenbaum R. Chemotherapy for elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 95 (2003) 341-343
2. Hutchins L.F., Unger J.M., Crowley J.J., Coltman Jr. C.A., and Albain K.S. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 341 (1999) 20611-20617
3. Monfardini S., Sorio R., Boes G.H., Kaye S., and Serraino D. Entry and evaluation of elderly patients in European organization for research and treatment of cancer (EORTC) new-drugs-development studies. Cancer 76 (1995) 333-338
4. Hurria A., and Kris M.G. Management of lung cancer in older adults. CA Cancer J Clin 53 (2003) 325-341
5. Aapro M.S., Köhne C.H., Cohen H.J., and Extermann M. Never too old? Age should not be a barrier to enrollment in cancer clinical trials. Oncologist 10 (2005) 198-204
6. Non-Small-Cell Lung Cancer Collaborative Group. Chemotherapy in non-small-cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 311 (1995) 899-909.
7. Finkelstein D.M., Ettinger D.S., and Ruckdeschel J.C. Long-term survivors in metastatic non-small-cell lung cancer. An Eastern Cooperative Oncology Group Study. J Clin Oncol 4 (1986) 702-709
8. Jiroutek M., Johnson D., and Blum R. Prognostic factors in advanced non-small-cell lung cancer (NSCLC): analysis of Eastern Cooperative Oncology Group (ECOG) trials from 1981-1992. Proc ASCO 17 (1998) 461A
9. The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell-lung cancer. J Natl Cancer Inst 91 (1999) 66-72
10. Feliu J., Martin G., Madronal C., Rodriguez-Jaraiz A., Castro J., Rodriguez A., et al. Combination of low-dose cisplatin and gemcitabine for treatment of elderly patients with advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 52 3 (2003) 247-252
11. Langer C.J., Manola J., Bernardo P., Kugler K.W., Bonomi P., Cella D., et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 94 (2002) 173-181
12. National Cancer Institute. Investigator's Handbook: A Manual for Participants in Clinical Trials of an Investigational Agents Sponsored by DCTD, NCI (1993.), National Cancer Institute, Bethesda, MD
13. Kaplan F.L., and Meier P. Nonparametric estimation from incomplete estimation. J Am Stat Assoc 53 (1958) 457-481
14. Mantel N. Evaluation of survival data and two new rank order statistics arise in its consideration. Cancer Chemother Rep 50 (1966) 163-170
15. Gridelli C., and Shepherd F.A. Chemotherapy for elderly patients with non-small-cell lung cancer: a review of evidence. Chest 128 (2005) 947-957
16. Gridelli C. Chemotherapy in elderly patients. Lung Cancer 49 (2005) S42-S43
17. Pereira J.R., Martins S.J., Nikaedo S.M., and Ikari F.K. Cheomotherapy with cisplatin and vinorelbine for elderly patients with locally advanced or metastatic non-small-cell lug cancer (NSCLC). BMC Cancer 4 (2004) 69-73
18. Chen Y.M.C., Perng R.P., Shih J.F., Tsai C.M., and Whang-Peng J. Chemotherapy for non-small-cell lung cancer elderly patients. Chest 128 (2005) 132-139
19. Guralnik J.M. Assessing the impact of comorbidity in the older population. Ann Epidemiol 6 (1996) 376-380
20. Extermann M., Overcash J., Lyman G.H., Parr J., and Balducci L. Comorbidity and functional status are independent in older patients. J Clin Oncol 16 (1998) 1582-1587
21. Zotano A.G., Ariño L.P., Saera J.M., Abad L.P., Lourenço J.P., Ortiz A.G., et al. Palliative chemotherapy and prognostic factors in elderly patients with non-small cell lung cancer (NSCLC). Lung Cancer 49 S2 (2005) S246, P491
22. Kelly K., Langer C., Rossel R., Hanna N., Sheepherd F., Einhorn L., et al. Elderly patients benefit from second-line cytotoxic chemotherapy for advanced non-small-cell lung cancer. Lung Cancer 49 S2 (2005) S251, P508